 |
|
Lipid-Lowering Therapy in Patients With Coronary Artery Disease: Sex or Age Bias?
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In their recent article, Miller et al1 highlight the relatively low and unchanged use of lipid-lowering agents among patients with coronary artery disease (CAD) at academic medical centers between 1994 and 1997. The picture appears disappointing overall and for women in particular. However, the use of lipid-lowering therapy (LLT) in the real world might be even less frequent. In fact, it is our opinion that the treatment figures obtained might be overestimations. First, patients participating in controlled clinical trials are usually highly motivated and more compliant with treatment than the general population. Second, the study involved medical centers of excellence in the United States and Canada. Third, when the results of the Scandinavian Simvastatin Survival Study were published in November 1994, a letter was distributed to all Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) investigators, thereby increasing the likelihood of physicians putting those recommendations into practice.
. . . [Full Text of this Article]
RELATED ARTICLES
Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada
Michael Miller, Robert Byington, Donald Hunninghake, Bertram Pitt, Curt D. Furberg, and for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial Investigators
Arch Intern Med. 2000;160(3):343-347.
ABSTRACT
| FULL TEXT
Cholesterol Lowering in the Elderly Population
Scott M. Grundy, James I. Cleeman, Basil M. Rifkind, Lewis H. Kuller, and for the Coordinating Committee of the National Cholesterol Education Program
Arch Intern Med. 1999;159(15):1670-1678.
ABSTRACT
| FULL TEXT
|
